250 related articles for article (PubMed ID: 36913303)
21. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
[TBL] [Abstract][Full Text] [Related]
22. The role of caspase-8 in resistance to cancer chemotherapy.
Kim PK; Mahidhara R; Seol DW
Drug Resist Updat; 2001 Oct; 4(5):293-6. PubMed ID: 11991682
[TBL] [Abstract][Full Text] [Related]
23. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
24. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
[TBL] [Abstract][Full Text] [Related]
25. Cyclotherapy: protection of normal cells and unshielding of cancer cells.
Blagosklonny MV; Darzynkiewicz Z
Cell Cycle; 2002; 1(6):375-82. PubMed ID: 12548008
[TBL] [Abstract][Full Text] [Related]
26. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
Lefranc F; Facchini V; Kiss R
Oncologist; 2007 Dec; 12(12):1395-403. PubMed ID: 18165616
[TBL] [Abstract][Full Text] [Related]
27. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
Kim H; Lee SJ; Lee IK; Min SC; Sung HH; Jeong BC; Lee J; Park SH
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325639
[TBL] [Abstract][Full Text] [Related]
29. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
Frost PJ; Belldegrun A; Bonavida B
Prostate; 1999 Sep; 41(1):20-30. PubMed ID: 10440872
[TBL] [Abstract][Full Text] [Related]
30. Experimental and computational assessment of the synergistic pharmacodynamic drug-drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells.
Vaidya TR; Ait-Oudhia S
J Pharmacokinet Pharmacodyn; 2022 Apr; 49(2):227-241. PubMed ID: 34773540
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment.
Spänkuch B; Strebhardt K
Curr Pharm Des; 2008; 14(11):1098-112. PubMed ID: 18473857
[TBL] [Abstract][Full Text] [Related]
32. Collateral sensitivity of natural products in drug-resistant cancer cells.
Efferth T; Saeed MEM; Kadioglu O; Seo EJ; Shirooie S; Mbaveng AT; Nabavi SM; Kuete V
Biotechnol Adv; 2020; 38():107342. PubMed ID: 30708024
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation.
Chow KU; Nowak D; Boehrer S; Ruthardt M; Knau A; Hoelzer D; Mitrou PS; Weidmann E
Biochem Pharmacol; 2003 Sep; 66(5):711-24. PubMed ID: 12948851
[TBL] [Abstract][Full Text] [Related]
34. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
35. Antagonistic drug combinations that select against drug resistance: from bacteria to cancer.
Blagosklonny MV
Cancer Biol Ther; 2007 Jul; 6(7):1013-4. PubMed ID: 17646740
[TBL] [Abstract][Full Text] [Related]
36. Taking advantage of drug resistance, a new approach in the war on cancer.
Wang L; Bernards R
Front Med; 2018 Aug; 12(4):490-495. PubMed ID: 30022460
[TBL] [Abstract][Full Text] [Related]
37. The ABCs of cancer stem cell drug resistance.
Elliott A; Adams J; Al-Hajj M
IDrugs; 2010 Sep; 13(9):632-5. PubMed ID: 20799146
[TBL] [Abstract][Full Text] [Related]
38. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
Knudsen ES; Witkiewicz AK
Trends Cancer; 2017 Jan; 3(1):39-55. PubMed ID: 28303264
[TBL] [Abstract][Full Text] [Related]
39. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
40. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
